ArticleNature communications2026
scTransMIL bridges patient-level disease states and single-cell transcriptomics for cancer screening and heterogeneity inference.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- scTransMIL bridges patient-level disease states and single-cell transcriptomics for cancer screening and heterogeneity inference.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell sequencing offers profound insights into tumor complexity. However, reliably linking individual cellular profiles to overall sample-level phenotypes remains computationally challenging, particularly when cell-specific annotations are absent. This disconnect limits the technology's utility in studying underlying tumor mechanisms. Here we show how scTransMIL, an artificial intelligence framework, bridges this gap. By conceptualizing a biological sample as a collection of individual cells, scTransMIL employs a transformer-based multi-instance learning approach to directly connect single-cell transcriptomic profiles with overarching sample-level labels. We demonstrate that scTransMIL accurately predicts sample-level cancer phenotypes, including the tissue-of-origin for metastatic tumors. At cellular resolution, it robustly identifies tumor-associated cell populations and maps biological progression trajectories using only minimal sample-level annotations. Furthermore, the model's attention mechanisms facilitate full-transcriptome biomarker discovery. By systematically integrating molecular and cellular scales with broader phenotypic states, our approach provides a computational tool to dissect tumor heterogeneity and advance fundamental cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.